BRIDGE AD 2025
Building BRidges to BrIng AntiamyloiD Monoclonal Antibodies to EliGible PatiEnts With Alzheimer’s Disease
Diagnostic performance of plasma pTau217, pTau181, Aβ1-42 and Aβ1-40 in the LUMIPULSE automated platform for the detection of Alzheimer disease.
Arranz J, Zhu N, Rubio-Guerra S, et al. Alz Res Therapy. 2024;16(1)139.
Detection and management of amyloid-related imaging abnormalities in patients with Alzheimer’s disease treated with anti-amyloid beta therapy.
Barakos J, Purcell D, Suhy J, et al. J Prev Alzheimers Dis. 2022;9(2):211-220.
Multiple cerebral hemorrhages in a patient receiving lecanemab and treated with t-PA for stroke.
Reish NJ, Jamshidi P, Stamm B, et al. N Engl J Med. 2023;388(5):478-479.
Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial.
Sims JR, Zimmer JA, Evans CD, et al. JAMA. 2023;330(6):512-527.
Lecanemab in early Alzheimer’s disease.
van Dyck CH, Swanson CJ, Aisen P, et al. N Engl J Med. 2023;388(1):9-21.
Clinical impact of microbleeds in patients with Alzheimer’s disease.
Vázquez-Justes D, Aguirregoicoa I, Fernandez L, et al. BMC Geriatrics. 2022;22(1):774.
Clinical Practice Guidelines
Lecanemab: appropriate use recommendations.
Cummings J, Apostolova L, Rabinovici GD, et al. J Prev Alzheimers Dis. 2023;10(3):362-377.
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer’s Association Workgroup
Jack CR, Jr., Andrews JS, Beach TG, et al. Alzheimers Dement. 2024;20(8):5143-5169.
International Nuclear Medicine Consensus on the clinical use of amyloid positron emission tomography in Alzheimer’s disease.
Tian M, Zuo C, Civelek AC, et al. Phenomics. 2023;3(4):375-389.
Clinician, Patient, and Caregiver Resources
AD8 dementia screening interview
Alzheimer’s Association
The Alzheimer’s Questionnaire
Monoclonal antibodies directed against amyloid for the treatment of Alzheimer’s disease CED study registry
Center for Medicare and Medicaid Services.
LEQEMBI® (lecanemab) prescribing information.
US Food and Drug Administration (FDA).
KISUNLA (donanemab) prescribing information.
FDA.
Mini-Mental State Exam (MMSE) Alzheimer’s / dementia test: administration, accuracy and scoring
Montreal Cognitive Assessment Test (MoCA) for dementia & Alzheimer’s
Standardized Mini-Cog© Instrument
15
2025
Neurology Center of New England, PC
Workshop 2
| Time: | 8:00 AM-9:00 AM ET |
| Venue: | Neurology Center of New England, PC |
| Location: | Foxboro, MA |
| Faculty: | David C. Weisman, MD |
18
2025
Neurology Center of New England, PC
Workshop 1
| Time: | 8:00 AM-9:00 AM ET |
| Venue: | Neurology Center of New England, PC |
| Location: | Foxboro, MA |
| Faculty: | David C. Weisman, MD |
10
2025
Penn State Neuroscience Institute
Workshop 1
| Time: | 2:00 PM-3:00 PM ET |
| Venue: | Penn State Neuroscience Institute |
| Location: | Hershey, PA |
| Faculty: | David C. Weisman, MD |
21
2025
Penn State Neuroscience Institute
Workshop 2
| Time: | 2:00 PM-3:00 PM ET |
| Venue: | Penn State Neuroscience Institute |
| Location: | Hershey, PA |
| Faculty: | David C. Weisman, MD |
